Navigation Links
Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
Date:9/14/2007

Long-Term Outlook More Favorable as Drugs from Eli Lilly and GlaxoSmithKline Will Drive the Market in 2016, According to a New Report

from Decision Resources

WALTHAM, Mass., Sept. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of Merck's Proscar and Boehringer Ingelheim/Astellas's Flomax/Harnal, combined with the limited emergence of new therapies, will cause a 23% decline in sales of therapies to treat benign prostatic hyperplasia over the next five years.

The new Pharmacor report entitled Benign Prostatic Hyperplasia finds that the market to treat the disease is dominated by two drug classes-alpha blockers and 5-alpha-reductase inhibitors-which make up 93% of drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. The report finds that the patent expiries of Proscar and Flomax/Harnal will cause a significant decline in the overall benign prostatic hyperplasia market by 2011.

Although patent expiries will constrain the market in the near term, increases in the patient population, unmet need, and higher drug treatment rates from 2011 to 2016 will help create a favorable landscape for novel benign prostatic hyperplasia treatments.

"Eli Lilly's Cialis and GlaxoSmithKline's fixed-dose combination of tamsulosin and dutasteride, both of which are expected to launch for benign prostatic hyperplasia in the United States and in Europe by 2011, are the two most promising agents in the pipeline," said Greg Dwyer, analyst at Decision Resources. "The combined sales of these two drugs will represent nearly 30% of the total benign prostatic hyperplasia market in 2016."

To listen to an interview with Mr. Dwyer regarding the benign prostatic hyperplasia drug market, please visit the Find Out More section of the Decision Resources home page on September 17, 2007, at http://www.DecisionResources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indian Doctor granted US patent on organ regeneration
2. Dr Reddy’s Laboratories to challenge patents on drug
3. Yoga, ayurveda being documented to stop patent misuse
4. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
5. US Court Rules Against Lupin in Ramipril Patent Case
6. HIV Patients Opposes Patenting Of AIDS Drug
7. Provigil Patent Extension Accorded To Cephalon
8. AIDS Sufferers Protest against Proposed Patent for Tenofovir
9. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
10. Venus Remedies Files 5th International Patent Application
11. Patent for Seminal RNAi innovation Cleared in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections Recovery ... now accredited by The Joint Commission for chemical dependency and behavioral health services. ... U.S. health care organizations that meet the commission’s rigorous standards. Accreditation by The ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... Clinical Plus Coating System for clients that rely on safety and cleanliness. This ... of microorganisms. , Silver has been used for centuries for its antimicrobial properties. ...
(Date:9/20/2017)... ... 2017 , ... Renal Support Network’s annual essay contest celebrates ... The theme “Describe a positive decision that you have made about your healthcare” ... one qualification— to have been diagnosed with chronic kidney disease. This year the ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer ... East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes ... 40 speakers — representing such thought-leading companies as JP Morgan Chase, GE ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/31/2017)... -- PM360,s annual Innovations Issue, published in December, ... happening across the industry. Established six years ago, this ... a comprehensive look at the newest and most exciting ... companies, startups, divisions, products, services, and strategies from the ... in this industry wants to do better—in all facets ...
Breaking Medicine Technology: